Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
NKTR Analyst Ratings
Moderate Buy
6 Buy
1 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NKTR Stock 12 Month Forecast
Average Price Target
$96.17
▲(236.85% Upside)
| Highest Price Target$120.00 | Average Price Target$96.17 | Lowest Price Target$69.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BTIG
$100
Buy
250.26%
Upside
Reiterated
08/08/25
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR)We hosted a webcast discussion last week with Dr. Charles Gropper (St. Sinai) who viewed REZPEG's therapeutic profile as a novel MOA favorably. Also of note, we hosted a dermatology payor call earlier this year, where it was unequivocally clear that new atopic dermatitis therapies that have at least parity efficacy vs. Dupixent should be warmly welcomed by the market. Looking ahead, we are focused on Phase 2b data of REZPEG in alopecia areata (REZOLVE-AA) expected in December 2025. JAK inhibitors are currently the only approved Tx for alopecia and come with significant safety concerns. Mgmt. considers efficacy similar to the JAK inhibitors (30-40% SALT reduction) as meaningful and while not required for success, even sees a compelling possibility for greater efficacy based on REZPEG's mechanism.
H.C. Wainwright
$120
Buy
320.32%
Upside
Reiterated
08/08/25
Piper Sandler
$105
Buy
267.78%
Upside
Reiterated
08/08/25
Oppenheimer
$90→$98
Buy
243.26%
Upside
Reiterated
08/08/25
William Blair
―
Hold
―
Reiterated
08/08/25
B.Riley Financial
$60→$85
Buy
197.72%
Upside
Reiterated
07/08/25
J.P. Morgan
―
Sell
―
Reiterated
06/24/25
Jefferies
$69
Buy
141.68%
Upside
Reiterated
06/24/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BTIG
$100
Buy
250.26%
Upside
Reiterated
08/08/25
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR)We hosted a webcast discussion last week with Dr. Charles Gropper (St. Sinai) who viewed REZPEG's therapeutic profile as a novel MOA favorably. Also of note, we hosted a dermatology payor call earlier this year, where it was unequivocally clear that new atopic dermatitis therapies that have at least parity efficacy vs. Dupixent should be warmly welcomed by the market. Looking ahead, we are focused on Phase 2b data of REZPEG in alopecia areata (REZOLVE-AA) expected in December 2025. JAK inhibitors are currently the only approved Tx for alopecia and come with significant safety concerns. Mgmt. considers efficacy similar to the JAK inhibitors (30-40% SALT reduction) as meaningful and while not required for success, even sees a compelling possibility for greater efficacy based on REZPEG's mechanism.
H.C. Wainwright
$120
Buy
320.32%
Upside
Reiterated
08/08/25
Piper Sandler
$105
Buy
267.78%
Upside
Reiterated
08/08/25
Oppenheimer
$90→$98
Buy
243.26%
Upside
Reiterated
08/08/25
William Blair
―
Hold
―
Reiterated
08/08/25
B.Riley Financial
$60→$85
Buy
197.72%
Upside
Reiterated
07/08/25
J.P. Morgan
―
Sell
―
Reiterated
06/24/25
Jefferies
$69
Buy
141.68%
Upside
Reiterated
06/24/25
Best Analysts Covering Nektar Therapeutics
1 Month
xxx
Success Rate
9/18 ratings generated profit
Average Return
+1.47%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.47% per trade.
3 Months
xxx
Success Rate
4/8 ratings generated profit
Average Return
+11.50%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +11.50% per trade.
1 Year
Success Rate
8/8 ratings generated profit
Average Return
+86.11%
reiterated a buy rating 28 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +86.11% per trade.
2 Years
xxx
Success Rate
8/8 ratings generated profit
Average Return
+86.11%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +86.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NKTR Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
11
10
9
11
11
Buy
0
0
0
0
0
Hold
5
10
16
19
16
Sell
1
0
3
3
3
Strong Sell
0
0
0
0
0
total
17
20
28
33
30
Each month's total comprises the sum of three months' worth of ratings.
NKTR Financial Forecast
NKTR Stock Forecast FAQ
What is NKTR’s average 12-month price target, according to analysts?
Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 96.17.
What is NKTR’s upside potential, based on the analysts’ average price target?
Nektar Therapeutics has 236.85% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NKTR a Buy, Sell or Hold?
Nektar Therapeutics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 1 hold ratings and 1 sell ratings.
What is Nektar Therapeutics’s price target?
The average price target for Nektar Therapeutics is 96.17. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $69.00. The average price target represents 236.85% Increase from the current price of $28.55.
The highest analyst price target is $120.00 ,the lowest forecast is $69.00. The average price target represents 236.85% Increase from the current price of $28.55.
What do analysts say about Nektar Therapeutics?
Nektar Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of NKTR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.